TACE与125I放射性粒子植入序贯治疗HCC的临床研究

目的：探讨经导管肝动脉化疗栓塞（TACE）与125I放射性粒子植入术序贯治疗肝细胞肝癌（hepatic carcinoma,HCC）的可行性和临床治疗效果。方法：回顾性研究确诊为HCC的患者86例,A组54例（单纯TACE组）,B组32例（TACE与125I放射性粒子植入术序贯治疗组）,通过对比观察患者肝功能、AFP、肿瘤大小变化、生存时间,分析TACE与125I放射性粒子植入术序贯治疗HCC的疗效。结果：术后3月A、B两组总体有效率（CR＋PR）分别为24.1%（13/54）、59.3%（19/32）,差异有显著性（P〈0.05）;术后1月A、B两组AFP下降差异有显著性（P〈0.05）;术后6月、12月、36月生存率B组为90.6%（29/32）、81.3%（26/32）、43.8%（14/32）,明显高于A组的48.1%（26/54）、33.3%（18/54）、18.5%（10/54）（P〈0.05）。结论：TACE与125I放射性粒子植入术序贯治疗HCC能达到较理想的治疗效果,是一种安全有效的方法。

Clinical study on sequential therapy of TACE combined with 125I radioactive particles implantation in hepatic carcinoma

Objective：To evaluate the feasibility and the clinic efficacy of sequential therapy of TACE combined with 125I radioactive particle implantation in hepatic carcinoma. Methods：86 cases of hepatic carcinoma were retrospectively collected and divided into two groups：54 patients in group A （TACE alone） 32 patients in group B （TACE combined with 125I radioactive particles implantation sequential therapy）. Hepatic function,AFP,the tumor volume and live time of 86 cases of the hepatic carcinoma were analyzed trpectively. Results：The overall response （CR＋PR） of group A and group B were 24.1%（13/54） and 59.3%（19/32） respectively 3 months after operation. There was a significant difference between them （P0.05）. AFP was decreased 1 month after operation in two groups,and the difference between them was significant. Survival rates of 6,12 and 36 months in group B（90.6%,81.3% and 43.8%） were higher than those in group A（48.1%,33.3% and 18.5%）（P0.05）.Conclusion：Sequential therapy of TACE combined with 125I radioactive particle implantation in treating hepatic carcinoma can get better therapeutic efficacy than TACE alone. It＇s a safe and effective method.